ProPhase Labs Q3 net revenue $3.1M (down 63% YoY); net loss $6.6M ($0.35/sh)

ProPhase Labs, Inc.

2024-Q3 EPS reported -$1.02 vs consensus $0.41 ▼ miss (-350.0%)

Net revenue $3.1M vs $8.4M in Q3 2023; net loss $6.6M ($0.35/sh) vs $5.1M ($0.30/sh).
Pharmaloz Manufacturing hired ThinkEquity to explore sale; projects $15M+ revenue over next 12 months.
BE-Smart esophageal cancer test initiated partnership talks with two billion-dollar diagnostic firms.
Equivir trial completed; final stats expected by end-November; preliminary data encouraging.
Cash $1.1M at Sep 30; plans to eliminate ~$6M/year overhead; working capital $13.5M.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.